 OyaGen is a biopharmaceutical company which develops therapies to fight viral illness through editing enzymes, with a focus on Human Immunodeficiency Virus (HIV).Founded with a seed fund by the University of Rochester and the Trillium Group, Smith has successfully brought in $6.5 million in Angel investment and $2.1 million in total federal grant support for OyaGen.In 2005, the company began preclinical trials on a drug that OyaGen believes will protect the body's natural A3G, which functions as an editing enzyme in mutating HIV DNA during its replication in such a way that the virus can no longer code for itself.